Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops aim to replace reading glasses – but are they safe Long-Term?

NCT ID NCT05753189

Disease control Sponsor: LENZ Therapeutics, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested the long-term safety of LNZ101 eye drops, a combination of aceclidine and brimonidine, in 362 adults aged 45-75 with presbyopia (age-related blurry near vision). Participants used the drops regularly and were monitored for side effects. The study is complete, and results will show how safe the drops are for ongoing use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aceclidine and brimonidine combination eye drops
What this could lead to
If successful, this could confirm that the eye drops are safe for long-term use to temporarily improve near vision without glasses.
What could go wrong
This is a safety study, not designed to prove effectiveness. Side effects like eye irritation or redness may occur, and the drops only work while they are being used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

362 people

The number who actually took part.

Started

Feb 2023

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study visits; 3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1; 4. Have +1.00 to -4.00 diopter (D) of sphere calculated in minus cylinder (so that spherical equivalent (SE) results in myopia no more severe than -4.00 D MRSE) in both eyes determined by manifest refraction documented at Visit 1; 5. Have ≤2.00 D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1; 6. Be presbyopic as determined at Visit 1 Exclusion Criteria: 1. Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy; 2. Have known contraindications or sensitivity to the use of any of the study medications or their components; 3. Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye; 4. Have moderate or severe dry eye defined as total central corneal fluorescein staining in either eye at Visit 1; 5. Have clinically significant abnormal lens findings including early lens changes during dilated slit lamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eye diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eye disorder myopia presbyopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eye diseases Near vision Presbyopia Refractive error

Contacts and locations

Locations

  • Site #301

    Overland Park, Kansas, 66210, United States

  • Site #302

    Chandler, Arizona, 85224, United States

  • Site #303

    Garden Grove, California, 92843, United States

  • Site #304

    Santa Barbara, California, 93105, United States

  • Site #306

    Petaluma, California, 94954, United States

  • Site #307

    Pittsburg, Kansas, 66762, United States

  • Site #308

    Littleton, Colorado, 80120, United States

  • Site #309

    Mt. Dora, Florida, 32757, United States

  • Site #310

    Fargo, North Dakota, 58103, United States

  • Site #311

    Smyrna, Tennessee, 37167, United States

  • Site #312

    Cranberry Township, Pennsylvania, 16066, United States

  • Site #313

    Glendale, California, 91204, United States

  • Site #314

    El Paso, Texas, 79902, United States

  • Site #315

    Memphis, Tennessee, 38104, United States

  • Site #316

    Danbury, Connecticut, 06810, United States

  • Site #317

    Rock Island, Illinois, 61201, United States

  • Site #318

    San Antonio, Texas, 78229, United States

  • Site #319

    Crystal River, Florida, 34429, United States

  • Site #320

    Mesa, Arizona, 85202, United States

  • Site #321

    Phoenix, Arizona, 85032, United States

  • Site #322

    Newport Beach, California, 92663, United States

  • Site #323

    Powell, Ohio, 43065, United States

  • Site #324

    Louisville, Kentucky, 40206, United States

  • Site #325

    St Louis, Missouri, 63128, United States

  • Site #326

    Dothan, Alabama, 36301, United States

  • Site #327

    San Antonio, Texas, 78229, United States

  • Site #328

    Phoenix, Arizona, 85053, United States

  • Site #329

    Cincinnati, Ohio, 45242, United States

  • Site #330

    Kansas City, Missouri, 64154, United States

  • Site #331

    Sun City, Arizona, 85351, United States

  • Site #332

    West Fargo, North Dakota, 58078, United States

  • Site #333

    Eugene, Oregon, 97401, United States

  • Site #334

    La Jolla, California, 92037, United States

  • Site #335

    Bozeman, Montana, 59718, United States

  • Site #336

    Alexandria, Minnesota, 56308, United States

  • Site #337

    Rancho Cordova, California, 95670, United States

  • Site #338

    Scottsdale, Arizona, 85260, United States

  • Site #339

    Morrow, Georgia, 30260, United States

  • Site #340

    Northbrook, Illinois, 60062, United States

  • Site #341

    Dover, New Jersey, 07801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.